
Antiepileptic drugs (AEDs) are commonly termed as anticonvulsants or antiseizure drugs, which are used in symptomatic treatment of epileptic seizures. The epileptic seizures show recurring episodes and occur due to wrong signal sent by nerve cells to the brain. Antiepileptic drugs also act as mood stabilizers and also used in the treatment of bipolar disorders or neuropathic pain. Antiepileptics market is specifically driven due to new drug approvals over the past few years. However, recent patent expiration of major brand such as Lamictal is expected to hinder the growth of the market. GlaxoSmithKline, Johnson & Johnson, Sanofi, Pfizer, Novartis, Abbott, Sunovion Pharmaceuticals, and Cephalon are some of the key leaders of global antiepileptic drugs market. Generic competition has dramatically increased for antiepileptics due to patent expiration of major brands and in future, it would be responsible for down pricing of branded drugs. Lyrica was the largest selling antiepileptic brand owing to its highly efficacious nature. Retigabine and perampanel are recently approved antiepileptics, which act through new molecular targets.